Molecular Subtype
Myeloproliferative Neoplasm, BCR-ABL1 Negative
CI-CAN-00003386Explore in graph →
Hematologic94 active trials2 approved drugs8 evidence items
- NCIt
- C198555
Loading cancer entity…
Molecular Subtype
CI-CAN-00003386Explore in graph →
Clinical trials
333 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (56)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06001385 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis(OPTIMIZE) | active not recruiting | Phase 2 | 313 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
| NCT02577926 | The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia(Ruxo-BEAT) | active not recruiting | Phase 2 | 207 | RWTH Aachen University |
| 1 |
| Aug 13, 2026 |
| clinicaltrials |
| NCT06985147 | A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | active not recruiting | Phase 2 | 60 | Disc Medicine, IncINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02506933 | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant | active not recruiting | Phase 2 | 102 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03862157 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03289910 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03441113 | Extended Access of Momelotinib in Adults With Myelofibrosis | active not recruiting | Phase 2 | 237 | GlaxoSmithKlineINDUSTRY | 20 | Jun 18, 2026 | clinicaltrials |
| NCT04517851 | Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05364762 | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | active not recruiting | Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04817007 | A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) | active not recruiting | Phase 1 / Phase 2 | 216 | Bristol-Myers SquibbINDUSTRY | 11 | May 8, 2026 | clinicaltrials |
| NCT05467800 | Study of Canakinumab in Patients With Myelofibrosis | active not recruiting | Phase 2 | 14 | John MascarenhasOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04262141 | IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) | active not recruiting | Phase 2 | 4 | Terrence J Bradley, MDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05499013 | Study to Assess SLN124 in Patients With Polycythemia Vera(SLN) | active not recruiting | Phase 1 / Phase 2 | 69 | Silence Therapeutics plcINDUSTRY | 9 | Dec 19, 2025 | clinicaltrials |
| NCT04060277 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | active not recruiting | Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT05482971 | A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET | active not recruiting | Phase 2 | 91 | PharmaEssentiaINDUSTRY | 2 | Aug 13, 2025 | clinicaltrials |
| NCT05485948 | A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU | active not recruiting | Phase 2 | 49 | PharmaEssentiaINDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03645824 | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)(HOVON134MF) | active not recruiting | Phase 2 | 61 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 2 | Aug 22, 2022 | clinicaltrials |
| NCT03669965 | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera | active not recruiting | Phase 2 | 20 | Kartos Therapeutics, Inc.INDUSTRY | 6 | Jul 31, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2026source: clinicaltrials